Antibiotics — Macrolides, Tetracyclines, Clindamycin

Mechanism of Action: Protein Synthesis Inhibition

• Macrolides and clindamycin irreversibly bind to the 50S ribosomal subunit, blocking peptide bond formation and preventing elongation of the nascent peptide chain. This inhibition is bacteriostatic and allows opsonization and clearance by phagocytes.
• Tetracyclines bind reversibly to the 30S ribosomal subunit, inhibiting aminoacyl-tRNA binding to the A site and preventing addition of amino acids to the growing chain. This is also bacteriostatic, allowing host immunity to eliminate the organism.
• Both mechanisms are selective for bacterial ribosomes (70S) over human mitochondrial ribosomes (80S), though some toxicity to mitochondria explains certain adverse effects (e.g., hepatotoxicity with macrolides in susceptible patients).

Spectrum of Activity Determinants

• Gram-positive coverage: All three classes are highly active against streptococci, staphylococci (though macrolide resistance is common), and some anaerobes. The cell wall penetration and ribosome binding affinity vary by drug structure.
• Atypical pathogen coverage: Macrolides and tetracyclines uniquely penetrate intracellular pathogens (Chlamydia, Mycoplasma, Legionella) due to superior intracellular accumulation; clindamycin has limited activity.
• Anaerobic coverage: Clindamycin penetrates abscesses and anaerobic environments better than macrolides due to superior tissue penetration and lower minimum inhibitory concentrations (MICs) for Bacteroides, Prevotella, and Peptostreptococcus species.

Tissue Penetration and Distribution

• Macrolides accumulate extensively in phagocytes (>50-fold concentration compared to serum), enabling treatment of intracellular infections and biofilm-forming organisms. They also achieve high concentrations in respiratory secretions, making them ideal for respiratory infections.
• Tetracyclines have excellent bone, lung, and CNS penetration; doxycycline achieves CSF levels 10-30% of serum levels, relevant for some meningitis cases. Lipophilic nature allows intracellular penetration.
• Clindamycin achieves excellent concentrations in bone, lung, and abscesses, making it superior for anaerobic infections in these sites. It also reaches therapeutic CNS levels (approximately 20% of serum).

Resistance Mechanisms

• Macrolide resistance develops through: (1) ribosomal methylation via erm genes (most common), producing MLSB phenotype (cross-resistance to clindamycin); (2) efflux pumps via mef genes; (3) enzymatic degradation (rare).
• Tetracycline resistance occurs via: (1) active efflux pumps (tet genes, most common); (2) ribosomal protection proteins; (3) enzymatic inactivation (rare); (4) ribosomal mutations.
• Clindamycin resistance develops through methylation (erm genes, same as macrolide resistance) or efflux. Importantly, inducible resistance to clindamycin can occur in Staphylococcus aureus and streptococci that are macrolide-resistant, requiring D-test confirmation of susceptibility.

• Community-acquired pneumonia (CAP) with atypical pathogens or as alternative to beta-lactams in penicillin-allergic patients; azithromycin is preferred due to once-daily dosing and better GI tolerability.
• Atypical infections: Chlamydia trachomatis, Mycoplasma pneumoniae, Legionella pneumophila, *Bordetella pertussis*—macrolides are often agents of choice due to intracellular penetration.
• Upper respiratory infections, pharyngitis (streptococcal), and sinusitis as alternatives to beta-lactams.
• Gastrointestinal infections: Azithromycin for Campylobacter, some Salmonella strains; clarithromycin for Helicobacter pylori (triple/quadruple therapy).
• Sexually transmitted infections: Azithromycin for chlamydial cervicitis and urethritis (increasingly used despite emerging resistance).
• Prophylaxis: Azithromycin prophylaxis for Mycobacterium avium complex (MAC) in AIDS patients with CD4 <50 cells/μL.

• Rickettsial infections (Rickettsia rickettsii, Orientia tsutsugamushi): Doxycycline is the first-line agent; tetracyclines are the only agents with proven mortality benefit in Rocky Mountain spotted fever.
• Atypical respiratory infections: Chlamydia, Mycoplasma, Legionella, and tick-borne respiratory pathogens.
• Sexually transmitted infections: Chlamydial infections (preferred agent due to cost, tolerability); gonorrhea (now rarely used due to widespread resistance); Mycoplasma genitalium (doxycycline for 7 days).
• Borrelial infections: Doxycycline is first-line for early Lyme disease and tick-borne relapsing fever.
• Acne and rosacea (tetracyclines have anti-inflammatory properties beyond antimicrobial activity).
• Antimalarial prophylaxis: Doxycycline for Plasmodium falciparum in chloroquine-resistant areas.
• Vibrio, Aeromonas, and other gram-negative coverage: Doxycycline for marine exposures and wound infections.
• Tigecycline: Broad-spectrum coverage including multidrug-resistant gram-negatives (ESBL-producing, Acinetobacter, resistant Pseudomonas) for complicated intra-abdominal and skin infections; reserved for resistant infections due to increased mortality risk.

Clinical Indications for Clindamycin

• Anaerobic infections: Intra-abdominal abscesses, aspiration pneumonia, bacteremia (especially Peptostreptococcus). Often superior to metronidazole for mixed aerobic-anaerobic infections.
• Bone and joint infections: Excellent bone penetration makes it first-line for anaerobic osteomyelitis and septic arthritis.
• Lung infections: Lung abscesses and anaerobic pneumonia due to superior abscess penetration.
• Staphylococcal infections: Methicillin-susceptible S. aureus (MSSA) when beta-lactams contraindicated, though resistance is increasing; particularly useful for skin and soft tissue infections.
• Streptococcal infections: Including group A streptococci for toxic shock syndrome (synergistic with IVIG) due to suppression of exotoxin production.
• Toxoplasmosis prophylaxis and treatment: In combination with pyrimethamine in AIDS (TMP-SMX preferred but clindamycin is alternative).
• Pneumocystis pneumonia (PCP): Clindamycin-primaquine is alternative therapy to TMP-SMX, particularly in sulfonamide-allergic patients.

Therapeutic Effects (What We Treat)

Respiratory Tract Infections

• Cough, dyspnea, fever, and sputum production in CAP caused by atypical pathogens respond to macrolides/tetracyclines due to intracellular concentration and lung penetration.
• Pertussis presents with paroxysmal cough ("whooping" cough), inspiratory stridor, and post-tussive vomiting—macrolides shorten the infectious period if given in the catarrhal stage.

Sexually Transmitted Infections

• Urethritis with dysuria, urethral discharge (often purulent with gonorrhea, mucopurulent with chlamydia), and pelvic pain respond to appropriate therapy. Chlamydial cervicitis may present with minimal symptoms (asymptomatic in ~75% of women), making screening essential.
• Azithromycin effectively clears Chlamydia (single 1-g dose) and Mycoplasma genitalium.

Rickettsial and Tick-Borne Infections

• Rocky Mountain spotted fever presents with fever, rash (starting on wrists/ankles, spreading centripetally, appearing 2-5 days into illness), myalgias, and headache—requires rapid doxycycline initiation even before confirmatory testing.
• Lyme disease: Early localized disease shows erythema migrans (expanding annular rash); doxycycline halts progression to disseminated disease if given promptly.

Anaerobic Infections

• Intra-abdominal infections present with abdominal pain, fever, and signs of peritonitis; clindamycin covers mixed aerobic-anaerobic flora when combined with coverage of gram-negatives (e.g., gentamicin).
• Lung abscess presents with productive cough, fever, and purulent/foul-smelling sputum due to anaerobic lung infection; clindamycin is superior to penicillin for penetrating the abscess cavity.
• Periodontal infections cause halitosis, gum tenderness, and tooth pain; oral anaerobes respond to clindamycin.

Adverse Effects (Drug-Related Presentations)

Gastrointestinal Effects

• Nausea, vomiting, abdominal cramping, and diarrhea are dose-dependent and concentration-dependent. Macrolides stimulate gastric motilin receptors, explaining prokinetic effects at low doses but GI upset at therapeutic doses.
• Clostridioides difficile-associated diarrhea (CDAD): Macrolides and clindamycin disrupt normal colonic flora, particularly clindamycin with reported CDAD incidence of 1-2% (vs. 0.3% for many other agents). Presentation ranges from mild diarrhea to fulminant colitis with fever, leukocytosis, and toxic megacolon.

Hepatotoxicity

• Macrolides (especially erythromycin) cause cholestatic hepatitis via mitochondrial toxicity. Erythromycin estolate formulation is particularly hepatotoxic; presents with jaundice, RUQ pain, and elevated transaminases (cholestatic pattern with ALP > ALT).
• Risk increases with age (>40 years), female gender, and prior macrolide exposure.

Cardiac Arrhythmias

• Macrolides (particularly erythromycin and azithromycin) prolong the QT interval via blockade of cardiac potassium channels (hERG channels). This increases risk of torsades de pointes, a potentially fatal polymorphic ventricular arrhythmia.
• Risk factors: female gender, hypokalemia, hypomagnesemia, bradycardia, concomitant QT-prolonging drugs, and hepatic impairment. Azithromycin carries black box warning for arrhythmias.

Photosensitivity

• Tetracyclines, particularly doxycycline and minocycline, cause photosensitive reactions on sun-exposed skin presenting as severe sunburn-like erythema after minimal sun exposure. This is phototoxic (not allergic) and dose-dependent.
• More common with older formulations; regular sun exposure counseling is essential.

CNS Effects

• Tetracyclines rarely cause intracranial hypertension ("pseudotumor cerebri"), especially in young women and those receiving isotretinoin concurrently. Presents with headache, visual disturbances, and papilledema.
• Minocycline can cause vestibular disturbances (vertigo, ataxia) and blue-gray pigmentation of skin, sclerae, and teeth.

Tooth Discoloration and Effects on Bone

• Tetracyclines chelate calcium and incorporate into developing teeth and bones, causing permanent yellow-brown discoloration and hypoplasia if administered during the second/third trimester or in children <8 years. This is irreversible and cosmetically significant.
• Osteoid formation may be impaired, though clinical consequences are generally minimal.

Other Drug-Related Effects

• Macrolide drug interactions: Potent CYP3A4 inhibitors (erythromycin > clarithromycin >> azithromycin) increase serum levels of drug substrates, notably increasing digoxin and statin levels.
• Tetracycline interactions: Form chelate complexes with divalent cations (Ca2+, Mg2+, Fe2+, Al3+), reducing absorption. Dairy products, antacids, and iron supplements impair absorption.
• QT prolongation: Macrolides and tigecycline can prolong QT interval; tigecycline carries black box warning for increased mortality in complicated infections (relative risk ~1.2).

Clinical Diagnosis and Pathogen Identification

Syndromic Clinical Assessment

• Respiratory tract infection with CAP pattern: Fever, cough, dyspnea, hypoxia, and infiltrate on chest imaging. Macrolides or tetracyclines are empiric coverage for atypical pathogens; clinical response (defervescence, improvement in oxygenation) within 48-72 hours supports correct therapy.
• Rickettsial infection suspicion: Fever, rash (petechial or macular, often involving palms/soles), and epidemiologic exposure (tick bite, endemic area). Doxycycline should be initiated empirically on clinical suspicion without awaiting confirmatory testing; delaying therapy increases mortality in RMSF.
• Anaerobic infection: Foul-smelling discharge, presentation after aspiration, or involvement of body cavity adjacent to mucous membranes suggests anaerobic infection; clindamycin empirically covers these pathogens.

Microbial Identification

Culture and Susceptibility Testing

• Gold standard: Bacterial culture with susceptibility testing guides definitive therapy. Respiratory specimens (sputum, BAL), urogenital swabs, blood, and abscess fluid should be cultured when possible.
• Fastidious organisms: Legionella requires buffered charcoal yeast extract (BCYE) medium and may not grow on routine culture; clinical suspicion and specialized culture requests are essential.
• Atypical pathogens: Mycoplasma requires special media and is often diagnosed serologically; Chlamydia requires intracellular culture (cell culture) or molecular methods (PCR/nucleic acid amplification tests [NAATs]).

Molecular/Nucleic Acid Amplification Tests (NAATs)

• Gold standard for diagnosis: NAATs (PCR) for Chlamydia trachomatis, Mycoplasma pneumoniae, and Mycoplasma genitalium have sensitivities >95% and specificities >98%.
• Respiratory specimens: Sputum PCR or nasopharyngeal swab PCR for Mycoplasma pneumoniae and Legionella pneumophila (urine antigen test for Legionella).
• Urogenital specimens: Urine or urethral/cervical swab NAATs for *Chlamy

Clindamycin — colonic flora destruction

• ***Clostridioides difficile* colitis**: the classic association. Loss of anaerobic colonization resistance permits overgrowth of toxigenic C. difficile (toxins A/B). Best next step is stopping the offending antibiotic; the 2021 IDSA/SHEA focused update recommends oral fidaxomicin (preferred) or oral vancomycin as initial therapy, with bezlotoxumab or fecal microbiota transplantation considered for recurrence. Oral metronidazole is now reserved for when neither preferred agent is available. There is no reversal agent.
• Other: morbilliform rash and DRESS, transaminase elevation, and potentiation of neuromuscular blocking agents.

Macrolides — channel and enzyme effects

• QT prolongation/torsades: hERG (I_Kr) potassium channel blockade delays repolarization. Check ECG and correct hypokalemia/hypomagnesemia before use in high-risk patients; avoid in congenital long QT or with other QT-prolonging drugs. Torsades is treated with IV magnesium sulfate — the closest thing to an antidote.
• CYP3A4 inhibition (erythromycin, clarithromycin; azithromycin negligible): raises levels of simvastatin/lovastatin (rhabdomyolysis), warfarin, colchicine, and calcineurin inhibitors. Azithromycin is the substitute when interaction risk is high.
• Cholestatic hepatitis (erythromycin estolate) and reversible sensorineural hearing loss at high doses.
• Infantile hypertrophic pyloric stenosis after erythromycin (and possibly azithromycin) in neonates under ~1 month — yet azithromycin remains the CDC-recommended pertussis agent in young infants, with counseling.

Tetracyclines — chelation and phototoxicity

• Teeth/bone: divalent-cation chelation deposits drug in mineralizing tissue → permanent discoloration and enamel hypoplasia; traditionally avoided in pregnancy and children <8 years. Exception: CDC and the AAP Red Book recommend doxycycline at any age for suspected rickettsial disease.
• Phototoxicity (not allergy), pill esophagitis (take upright with water), pseudotumor cerebri (avoid combining with isotretinoin/vitamin A).
• Minocycline: vestibular toxicity, blue-gray pigmentation, drug-induced lupus.
• Expired/degraded tetracycline → Fanconi-like proximal tubulopathy.
• Non-doxycycline tetracyclines are anti-anabolic and worsen azotemia; doxycycline is cleared non-renally and needs no renal adjustment.
• Tigecycline carries an FDA boxed warning for increased all-cause mortality and achieves low serum/urine levels — not for bacteremia or UTI.

• **Erythromycin-resistant, clindamycin-susceptible S. aureus → order a *D-test***: a flattened "D" shaped zone of inhibition indicates inducible *erm*-mediated MLS_B resistance, and clindamycin should not be used despite the susceptible report. This is the single most tested next step in the clindamycin stem.
• Suspected Rocky Mountain spotted fever → give doxycycline immediately, before serology and regardless of age. CDC and the AAP Red Book endorse doxycycline in children; the common distractor is withholding it for tooth staining or substituting chloramphenicol.
• Clindamycin in group A streptococcal toxic shock/necrotizing fasciitis: added to a beta-lactam because ribosomal blockade shuts off exotoxin synthesis and its efficacy is unaffected by high inoculum (Eagle effect), per the IDSA skin and soft tissue infection guideline. Penicillin alone is the distractor.
• Erythromycin is a motilin receptor agonist — the reason it causes cramping, and the reason it is used off-label as a prokinetic in diabetic gastroparesis.
• Macrolide + simvastatin/lovastatin → rhabdomyolysis via CYP3A4 inhibition. Azithromycin is the answer when a macrolide is required in a patient on interacting drugs; it does not meaningfully inhibit CYP3A4.
• Torsades de pointes on a macrolide → IV magnesium sulfate, plus correction of potassium and withdrawal of the drug.
• Fanconi syndrome from expired tetracycline — type 2 (proximal) RTA with glycosuria, aminoaciduria, and phosphaturia — is a recurring one-liner.
• Tetracycline absorption is destroyed by divalent cations: separate from dairy, antacids, calcium, iron, and sucralfate. A "treatment failure" stem in a patient taking antacids is testing chelation, not resistance.
• Uncomplicated chlamydia: the 2021 CDC STI Treatment Guidelines favor doxycycline for 7 days over single-dose azithromycin, with azithromycin retained in pregnancy.
• Community-acquired pneumonia: the 2019 ATS/IDSA guideline no longer endorses macrolide monotherapy where pneumococcal macrolide resistance is common — pair it with a beta-lactam or use doxycycline.